Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions

Herman Nilsson-Ehle; Gunnar Birgegård; Jan Samuelsson; Petar Antunovic; Jan Astermark; Hege Garelius; Lena M Engström; Lars Kjeldsen; Lars Ola Nilsson; Anna Olsson; Mette Skov-Holm; Jonas Wallvik; Nina Gulbrandsen; Eva Hellström-Lindberg

doi:10.1111/j.1600-0609.2011.01654.x

Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions

Herman Nilsson-Ehle, Gunnar Birgegård, Jan Samuelsson, Petar Antunovic, Jan Astermark, Hege Garelius, Lena M Engström, Lars Kjeldsen, Lars Ola Nilsson, Anna Olsson, Mette Skov-Holm, Jonas Wallvik, Nina Gulbrandsen, Eva Hellström-Lindberg

52 Citationer (Scopus)

Abstrakt

Anaemia in low-risk myelodysplastic syndromes (MDS) is associated with reduced quality of life (QoL). Response to treatment with erythropoietin ± granulocyte colony-stimulating factor (G-CSF) is associated with improved QoL, but whether transfusion therapy with higher haemoglobin (Hb) target levels has similar effects is unknown. The objective for this prospective phase II Nordic multicentre trial was to assess QoL, response rate and physical function in elderly anaemic MDS patients treated to a target Hb level of >120 g/L.

Originalsprog	Engelsk
Tidsskrift	European Journal of Haematology
Vol/bind	87
Udgave nummer	3
Sider (fra-til)	244-52
Antal sider	9
ISSN	0902-4441
DOI	https://doi.org/10.1111/j.1600-0609.2011.01654.x
Status	Udgivet - 2011

Adgang til dokumentet

10.1111/j.1600-0609.2011.01654.x

Citationsformater

Nilsson-Ehle, H., Birgegård, G., Samuelsson, J., Antunovic, P., Astermark, J., Garelius, H., Engström, L. M., Kjeldsen, L., Nilsson, L. O., Olsson, A., Skov-Holm, M., Wallvik, J., Gulbrandsen, N., & Hellström-Lindberg, E. (2011). Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions. European Journal of Haematology, 87(3), 244-52. https://doi.org/10.1111/j.1600-0609.2011.01654.x

Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions. / Nilsson-Ehle, Herman; Birgegård, Gunnar; Samuelsson, Jan et al.

I: European Journal of Haematology, Bind 87, Nr. 3, 2011, s. 244-52.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Nilsson-Ehle, H, Birgegård, G, Samuelsson, J, Antunovic, P, Astermark, J, Garelius, H, Engström, LM, Kjeldsen, L, Nilsson, LO, Olsson, A, Skov-Holm, M, Wallvik, J, Gulbrandsen, N & Hellström-Lindberg, E 2011, 'Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions', European Journal of Haematology, bind 87, nr. 3, s. 244-52. https://doi.org/10.1111/j.1600-0609.2011.01654.x

Nilsson-Ehle H, Birgegård G, Samuelsson J, Antunovic P, Astermark J, Garelius H et al. Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions. European Journal of Haematology. 2011;87(3):244-52. https://doi.org/10.1111/j.1600-0609.2011.01654.x

@article{20e1e4a545194e3d897d2897cf578475,

title = "Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions",

abstract = "Anaemia in low-risk myelodysplastic syndromes (MDS) is associated with reduced quality of life (QoL). Response to treatment with erythropoietin ± granulocyte colony-stimulating factor (G-CSF) is associated with improved QoL, but whether transfusion therapy with higher haemoglobin (Hb) target levels has similar effects is unknown. The objective for this prospective phase II Nordic multicentre trial was to assess QoL, response rate and physical function in elderly anaemic MDS patients treated to a target Hb level of >120 g/L.",

keywords = "Aged, Aged, 80 and over, Erythrocyte Transfusion, Erythropoietin, Female, Ferritins, Granulocyte Colony-Stimulating Factor, Hemoglobins, Humans, Magnetic Resonance Imaging, Male, Myelodysplastic Syndromes, Quality of Life, Recombinant Proteins, Treatment Outcome",

author = "Herman Nilsson-Ehle and Gunnar Birgeg{\aa}rd and Jan Samuelsson and Petar Antunovic and Jan Astermark and Hege Garelius and Engstr{\"o}m, {Lena M} and Lars Kjeldsen and Nilsson, {Lars Ola} and Anna Olsson and Mette Skov-Holm and Jonas Wallvik and Nina Gulbrandsen and Eva Hellstr{\"o}m-Lindberg",

note = "{\textcopyright} 2011 John Wiley & Sons A/S.",

year = "2011",

doi = "10.1111/j.1600-0609.2011.01654.x",

language = "English",

volume = "87",

pages = "244--52",

journal = "European Journal of Haematology",

issn = "0902-4441",

publisher = "Wiley-Blackwell Munksgaard",

number = "3",

}

TY - JOUR

T1 - Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions

AU - Nilsson-Ehle, Herman

AU - Birgegård, Gunnar

AU - Samuelsson, Jan

AU - Antunovic, Petar

AU - Astermark, Jan

AU - Garelius, Hege

AU - Engström, Lena M

AU - Kjeldsen, Lars

AU - Nilsson, Lars Ola

AU - Olsson, Anna

AU - Skov-Holm, Mette

AU - Wallvik, Jonas

AU - Gulbrandsen, Nina

AU - Hellström-Lindberg, Eva

PY - 2011

Y1 - 2011

N2 - Anaemia in low-risk myelodysplastic syndromes (MDS) is associated with reduced quality of life (QoL). Response to treatment with erythropoietin ± granulocyte colony-stimulating factor (G-CSF) is associated with improved QoL, but whether transfusion therapy with higher haemoglobin (Hb) target levels has similar effects is unknown. The objective for this prospective phase II Nordic multicentre trial was to assess QoL, response rate and physical function in elderly anaemic MDS patients treated to a target Hb level of >120 g/L.

AB - Anaemia in low-risk myelodysplastic syndromes (MDS) is associated with reduced quality of life (QoL). Response to treatment with erythropoietin ± granulocyte colony-stimulating factor (G-CSF) is associated with improved QoL, but whether transfusion therapy with higher haemoglobin (Hb) target levels has similar effects is unknown. The objective for this prospective phase II Nordic multicentre trial was to assess QoL, response rate and physical function in elderly anaemic MDS patients treated to a target Hb level of >120 g/L.

KW - Aged

KW - Aged, 80 and over

KW - Erythrocyte Transfusion

KW - Erythropoietin

KW - Female

KW - Ferritins

KW - Granulocyte Colony-Stimulating Factor

KW - Hemoglobins

KW - Humans

KW - Magnetic Resonance Imaging

KW - Male

KW - Myelodysplastic Syndromes

KW - Quality of Life

KW - Recombinant Proteins

KW - Treatment Outcome

U2 - 10.1111/j.1600-0609.2011.01654.x

DO - 10.1111/j.1600-0609.2011.01654.x

M3 - Journal article

C2 - 21623919

VL - 87

SP - 244

EP - 252

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 3

ER -

Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions

Abstrakt

Adgang til dokumentet

Fingeraftryk

Citationsformater